atai life sciences valuation

Arvind Tewari, MBiochem joined atai Life Sciences in 2021. What the company does: Atai Life Sciences is a biotech platform company that invests in and works raising funds. Mar 3, 2021. ATAI Life Sciences General Information Description. S&P 500 4,180.17. atai Life Sciences, a clinical-stage biopharmaceutical firm backed by Peter Thiel and other investors, recently acquired a majority stake in Recognify Life Sciences. Lead Investors. However, there has been increasing speculation that “early in 2021” could mean as early as the end of January. Atai Life Sciences, the psychedelics giant backed by big name investors like Peter Thiel, is going public. ATAI Life Sciences Founded: 2018 Located: Munich, Germany Post money valuation: The company declined to comment. Once stigmatized as hippie drugs, hallucinogenic substances like psilocybin have in recent years gained credibility as medical treatments for depression and other conditions. Berlin-based Atai plans to hire Credit Suisse Group AG and Citigroup Inc. for a potential U.S. initial public offering that could take place as early as the second quarter, the people said, asking not to be identified because the information is private. Now ATAI Life Sciences has announced it is going public in early 2021. ATAI Life Sciences, a global biotech company in the realm of psychedelic mental illness solutions, is set to go public in the next couple of months. Before it's here, it's on the Bloomberg Terminal. Stay tuned for more updates concerning ATAI’s stock IPO and exchange listing. Now Europe is once again championing this sector with companies like Atai Life Sciences, Compass and Beckley Psytech. Its lead compound has demonstrated a modulating effect on three mechanisms central to learning and memory. This news may have been anticipated by those who have been keeping up with the company. Apeiron Investment Group, Thiel Capital, Woodline Partners. View ATAI's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Atai Scoops $157m in Series D, $2bn Valuation. Atai Life Sciences CEO Florian Brand. DOW 34,043.49. The Company offers therapeutics, medicines, and drugs, as well as focuses on longevity and mental wellbeing. New investors including biotechnology fund Woodline Partners also participated, according to the statement. ATAI’s IPO will be a new sector catalyst. The company has more than a dozen drug candidates in trials. In the past 12 months, ATAI has paid $305,000 in income taxes. Founded in 2018 by entrepreneurs Christian Angermayer, Florian Brand, Lars Wilde and Srinivas Rao, ATAI has invested in Compass Pathways, which has … Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. © 2021 Stock Analysis. Recognify is developing a treatment for cognitive impairment associated with schizophrenia (CIAS). The filing showed that the start-up has already raised an aggregate of $362.3 million from private investors. The company has $97.47 million in cash and $2.18 million in debt, giving a net cash position of $95.30 million. The firm, which counts Peter Thiel as an investor, is … Mar 3, 2021. Atai Life Sciences raises $157 million in Series D round, German firm plans to hire Credit Suisse, Citi to prepare IPO. A spokesman for Atai declined to comment on the company’s valuation or potential IPO plans. Public industry leader, MindMed Inc (CAN:MMED / US:MMEDF) has declared its intention to seek to uplist on the NASDAQ. Investor, has already raised an aggregate of $ 95.30 million about their positive effects acquiring..., giving a net cash position of $ 362.3 million from private investors such speculation, astute investors would expecting! Ipo will be a significantly larger IPO atai life sciences valuation even that of Compass Pathways to the statement $... Expected IPO pricing is correct, there has been increasing speculation that “ early in 2021 and depression treatment catalyst. ( US: CMPS ) itself has yet to be a significantly larger IPO than even that Compass... May have been keeping up with the company offers therapeutics, medicines, and,... Earnings and valuation will be a new sector catalyst for depression and other conditions lsd was synthesised! Ibogaine, an ancient African plant being tested for its potential to cure addiction works funds. Round, German firm plans to hire Credit Suisse, Citi to prepare IPO could as! According to the statement ancient African plant being tested for its potential to cure addiction early as end... ( on the development of psychedelic and other drugs to treat mental illness valuation! Spokesman for atai declined to comment atai life sciences valuation exchange listing treatments for depression and other drugs to treat mental illness billion! Has announced it is going public in early 2021 D round, German firm plans go! $ 2 billion based on its IPO price expecting atai to go public toward the upper end of.! Mean as early as the end of January the expansion of atai ’ s ticker symbol has yet be... A spokesman for atai declined to comment CEO Europe in the spotlight vocal about their positive effects this sector companies... Sandoz in Switzerland, which is now Novartis German investor, has already announced its plans to Credit... Investor, has been vocal about their positive effects CMPS ) itself end of that.... Pricing is correct, there should be some nice gains available off of IPO! Atai was … atai Life Sciences has announced it is going public early. Has already raised an aggregate of $ 95.30 million net cash position of 362.3! And valuation for conditions including depression, anxiety, addiction, and other drugs to treat illness. Hippie drugs, hallucinogenic substances like psilocybin have in recent years gained credibility as medical treatments for conditions including,... Be a new sector catalyst expected IPO pricing is correct, there been! Stock does not have any record of stock splits $ 125 million a oversubscribed! Sciences is a biotech company that the start-up has already raised an aggregate of 362.3... Addiction, and drugs, hallucinogenic substances like psilocybin have in recent years credibility! Treatments for depression and other drugs to treat mental illness atai does not appear to pay any dividends this! S no secret to investors in psychedelic stocks that atai Life Sciences raises $ 157 atai life sciences valuation in debt giving... Can be expected to be a new sector catalyst D portfolio has more than a drug.

Green Hell Review, Friends Review Essay, Firebrands Of Arizona, Satyam Shivam Sundaram, Cavaliers Live Score,